Detalhe da pesquisa
1.
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
N Engl J Med
; 387(12): 1089-1098, 2022 09 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36027570
2.
Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial.
Circulation
; 148(22): 1735-1745, 2023 11 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-37632455
3.
Patient Characteristics, Outcomes, and Effects of Dapagliflozin According to the Duration of Heart Failure: A Prespecified Analysis of the DELIVER Trial.
Circulation
; 147(14): 1067-1078, 2023 04 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36876483
4.
Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER.
Circulation
; 147(8): 624-634, 2023 02 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-36342789
5.
Dapagliflozin and Blood Pressure in Patients with Chronic Kidney Disease and Albuminuria.
Am Heart J
; 270: 125-135, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38367893
6.
Heart Failure, Investigator-Reported Sleep Apnea and Dapagliflozin: A Patient-Level Pooled Meta-Analysis of DAPA-HF and DELIVER.
J Card Fail
; 30(3): 436-448, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38104937
7.
Effects of Dapagliflozin in Chronic Kidney Disease Across the Spectrum of Age and by Sex.
J Gen Intern Med
; 39(6): 921-930, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38097862
8.
Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease : A Post Hoc Analysis of DAPA-CKD.
Ann Intern Med
; 176(1): 59-66, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36469914
9.
Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial.
Circulation
; 145(3): 158-169, 2022 01 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34743554
10.
Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials.
Circulation
; 145(19): 1460-1470, 2022 05 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35394821
11.
Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF.
Circulation
; 146(13): 980-994, 2022 09 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-35971840
12.
Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF.
Circulation
; 146(6): 438-449, 2022 08 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35442064
13.
Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial.
Circulation
; 145(21): 1581-1591, 2022 05 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35510542
14.
Dapagliflozin in Patients with Chronic Kidney Disease.
N Engl J Med
; 383(15): 1436-1446, 2020 10 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32970396
15.
Rationale and design of the DAPA-MI trial: Dapagliflozin in patients without diabetes mellitus with acute myocardial infarction.
Am Heart J
; 266: 188-197, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37648579
16.
Operational challenges and mitigation measures during the COVID-19 pandemic-Lessons from DELIVER.
Am Heart J
; 263: 133-140, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37220822
17.
Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial.
Cardiovasc Diabetol
; 22(1): 330, 2023 11 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38017482
18.
Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction : A Post Hoc Analysis of the DAPA-HF Trial.
Ann Intern Med
; 175(6): 820-830, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35467935
19.
Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKD.
J Am Soc Nephrol
; 33(11): 2094-2107, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35977807
20.
Dapagliflozin for heart failure according to body mass index: the DELIVER trial.
Eur Heart J
; 43(41): 4406-4417, 2022 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36029309